APPL1 transgenic mice are protected from high-fat diet-induced cardiac dysfunction

American Journal of Physiology - Endocrinology and Metabolism

Volumn 305, Issue 7, 2013, Pages

  Park, Min ^a   Wu, Donghai ^b   Park, Taesik ^c   Choi, Cheol Soo ^c   Li, Ren Ke ^d   Cheng, Kenneth K Y ^e   Xu, Aimin ^e   Sweeney, Gary ^a  

^a YORK UNIVERSITY   (Canada)

^b GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

^c Gachon University   (South Korea)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Cardiac function; Cardiomyopathy; High fat diet; Insulin sensitivity; Lipotoxicity; Nonesterified; Oxidative stress

Indexed keywords

ADAPTOR PROTEIN; APPL1 PROTEIN; CERAMIDE; DIACYLGLYCEROL; SPHINGOMYELIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; ECHOCARDIOGRAPHY; GLUCOSE TOLERANCE TEST; GLUCOSE TRANSPORT; HEART DISEASE; HEART EJECTION FRACTION; INSULIN RESISTANCE; INSULIN RESPONSE; LIPID DIET; LIPID STORAGE; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE; WILD TYPE;

CARDIAC FUNCTION; CARDIOMYOPATHY; HIGH-FAT DIET; INSULIN SENSITIVITY; LIPOTOXICITY; NONESTERIFIED; OXIDATIVE STRESS;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; BODY WEIGHT; CARDIOMYOPATHIES; DIET, HIGH-FAT; GLUCOSE; GLUCOSE TOLERANCE TEST; INSULIN; INSULIN RESISTANCE; LIPIDS; MICE; MICE, TRANSGENIC; MYOCYTES, CARDIAC; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 84884946232     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00257.2013     Document Type: Article

References (51)

1. Abel ED. Myocardial insulin resistance and cardiac complications of diabetes. Curr Drug Targets Immune Endocr Metabol Disord 5: 219-226, 2005.
2. Abel ED, Litwin SE, Sweeney G. Cardiac remodeling in obesity. Physiol Rev 88: 389-419, 2008.
3. Adeghate E, Singh J. Structural changes in the myocardium during diabetes-induced cardiomyopathy. Heart Fail Rev, 2013 Mar 7 [Epub ahead of print] 23467937 PMID.
4. Ahren J, Ahren B, Wierup N. Increased beta-cell volume in mice fed a high-fat diet: a dynamic study over 12 months. Islets 2: 353-356, 2010.
5. Bauer M, Cheng S, Jain M, Ngoy S, Theodoropoulos C, Trujillo A, Lin FC, Liao R. Echocardiographic speckle-tracking based strain imaging for rapid cardiovascular phenotyping in mice. Circ Res 108: 908-916, 2011.
6. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37: 911-917, 1959.
7. Boudina S, Abel ED. Diabetic cardiomyopathy, causes and effects. Rev Endocr Metab Disord 11: 31-39, 2010.
8. Cheng KK, Iglesias MA, Lam KS, Wang Y, Sweeney G, Zhu W, Vanhoutte PM, Kraegen EW, Xu A. APPL1 potentiates insulin-mediated inhibition of hepatic glucose production and alleviates diabetes via Akt activation in mice. Cell Metab 9: 417-427, 2009.
9. Cheng KK, Lam KS, Wang Y, Huang Y, Carling D, Wu D, Wong C, Xu A. Adiponectin-induced endothelial nitric oxide synthase activation and nitric oxide production are mediated by APPL1 in endothelial cells. Diabetes 56: 1387-1394, 2007.
10. Cheng KK, Lam KS, Wu D, Wang Y, Sweeney G, Hoo RL, Zhang J, Xu A. APPL1 potentiates insulin secretion in pancreatic beta cells by enhancing protein kinase Akt-dependent expression of SNARE proteins in mice. Proc Natl Acad Sci USA 109: 8919-8924, 2012.
11. Chiu HC, Kovacs A, Ford DA, Hsu FF, Garcia R, Herrero P, Saffitz JE, Schaffer JE. A novel mouse model of lipotoxic cardiomyopathy. J Clin Invest 107: 813-822, 2001.
12. Cleasby ME, Lau Q, Polkinghorne E, Patel SA, Leslie SJ, Turner N, Cooney GJ, Xu A, Kraegen EW. The adaptor protein APPL1 increases glycogen accumulation in rat skeletal muscle through activation of the PI3-kinase signalling pathway. J Endocrinol 210: 81-92, 2011.
13. Cottrell C, Kirkpatrick JN. Echocardiographic strain imaging and its use in the clinical setting. Expert Rev Cardiovasc Ther 8: 93-102, 2010.
14. Deepa SS, Dong LQ. APPL1: role in adiponectin signaling and beyond. Am J Physiol Endocrinol Metab 296: E22-E36, 2009.
15. Deepa SS, Zhou L, Ryu J, Wang C, Mao X, Li C, Zhang N, Musi N, DeFronzo RA, Liu F, Dong LQ. APPL1 mediates adiponectin-induced LKB1 cytosolic localization through the PP2A-PKCzeta signaling pathway. Mol Endocrinol 25: 1773-1785, 2011.
16. Dirkx E, Schwenk RW, Glatz JF, Luiken JJ, van Eys GJ. High fat diet induced diabetic cardiomyopathy. Prostaglandins Leukot Essent Fatty Acids 85: 219-225, 2011.
17. Drosatos K, Bharadwaj KG, Lymperopoulos A, Ikeda S, Khan R, Hu Y, Agarwal R, Yu S, Jiang H, Steinberg SF, Blaner WS, Koch WJ, Goldberg IJ. Cardiomyocyte lipids impair β-adrenergic receptor function via PKC activation. Am J Physiol Endocrinol Metab 300: E489-E499, 2011.
18. Fang X, Palanivel R, Cresser J, Schram K, Ganguly R, Thong FS, Tuinei J, Xu A, Abel ED, Sweeney G. An APPL1-AMPK signaling axis mediates beneficial metabolic effects of adiponectin in the heart. Am J Physiol Endocrinol Metab 299: E721-E729, 2010.
19. Finck BN, Han X, Courtois M, Aimond F, Nerbonne JM, Kovacs A, Gross RW, Kelly DP. A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc Natl Acad Sci USA 100: 1226-1231, 2003.
20. Ghosh S, Rodrigues B. Cardiac cell death in early diabetes and its modulation by dietary fatty acids. Biochim Biophys Acta 1761: 1148-1162, 2006.
21. Holland WL, Miller RA, Wang ZV, Sun K, Barth BM, Bui HH, Davis KE, Bikman BT, Halberg N, Rutkowski JM, Wade MR, Tenorio VM, Kuo MS, Brozinick JT, Zhang BB, Birnbaum MJ, Summers SA, Scherer PE. Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat Med 17: 55-63, 2011.
22. Holmes RM, Yi Z, De Filippis E, Berria R, Shahani S, Sathyanarayana P, Sherman V, Fujiwara K, Meyer C, Christ-Roberts C, Hwang H, Finlayson J, Dong LQ, Mandarino LJ, Bajaj M. Increased abundance of the adaptor protein containing pleckstrin homology domain, phosphotyrosine binding domain and leucine zipper motif (APPL1) in patients with obesity and type 2 diabetes: evidence for altered adiponectin signalling. Diabetologia 54: 2122-2131, 2011.
23. Hosch SE, Olefsky JM, Kim JJ. APPLied mechanics: uncovering how adiponectin modulates insulin action. Cell Metab 4: 5-6, 2006.
24. Itani SI, Ruderman NB, Schmieder F, Boden G. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB-alpha. Diabetes 51: 2005-2011, 2002.
25. Khan RS, Drosatos K, Goldberg IJ. Creating and curing fatty hearts. Curr Opin Clin Nutr Metab Care 13: 145-149, 2010.
26. Liu Y, Turdi S, Park T, Morris NJ, Deshaies Y, Xu A, Sweeney G. Adiponectin corrects high-fat diet-induced disturbances in muscle metabolomic profile and whole-body glucose homeostasis. Diabetes 62: 743-752, 2013.
27. Mao X, Kikani CK, Riojas RA, Langlais P, Wang L, Ramos FJ, Fang Q, Christ-Roberts CY, Hong JY, Kim RY, Liu F, Dong LQ. APPL1 binds to adiponectin receptors and mediates adiponectin signalling and function. Nat Cell Biol 8: 516-523, 2006.
28. Marinho R, Ropelle E, Cintra D, De Souza C, Da Silva A, Bertoli F, Colantonio E, D'Almeida V, Pauli J. Endurance exercise training increases APPL1 expression and improves insulin signaling in the hepatic tissue of diet-induced obese mice, independently of weight loss. J Cell Physiol 227: 2917-2926, 2011.
29. Mitsuuchi Y, Johnson SW, Sonoda G, Tanno S, Golemis EA, Testa JR. Identification of a chromosome 3p14.3-211 gene, APPL, encoding an adaptor molecule that interacts with the oncoprotein-serine/threonine kinase AKT2. Oncogene 18: 4891-4898, 1999.
30. Mondillo S, Galderisi M, Mele D, Cameli M, Lomoriello VS, Zaca V, Ballo P, D'Andrea A, Muraru D, Losi M, Agricola E, D'Errico A, Buralli S, Sciomer S, Nistri S, Badano L. Speckle-tracking echocardiography: a new technique for assessing myocardial function. J Ultrasound Med 30: 71-83, 2011.
31. Ouchi N, Shibata R, Walsh K. Cardioprotection by adiponectin. Trends Cardiovasc Med 16: 141-146, 2006.
32. Palanivel R, Fang X, Park M, Eguchi M, Pallan S, De Girolamo S, Liu Y, Wang Y, Xu A, Sweeney G. Globular and full-length forms of adiponectin mediate specific changes in glucose and fatty acid uptake and metabolism in cardiomyocytes. Cardiovasc Res 75: 148-157, 2007.
33. Park M, Youn B, Zheng XL, Wu D, Xu A, Sweeney G. Globular adiponectin, acting via AdipoR1/APPL1, protects H9c2 cells from hypoxia/ reoxygenation-induced apoptosis. PLoS One 6: e19143, 2011.
34. Park TS, Hu Y, Noh HL, Drosatos K, Okajima K, Buchanan J, Tuinei J, Homma S, Jiang XC, Abel ED, Goldberg IJ. Ceramide is a cardiotoxin in lipotoxic cardiomyopathy. J Lipid Res 49: 2101-2112, 2008.
35. Peng Y, Popovic ZB, Sopko N, Drinko J, Zhang Z, Thomas JD, Penn MS. Speckle tracking echocardiography in the assessment of mouse models of cardiac dysfunction. Am J Physiol Heart Circ Physiol 297: H811-H820, 2009.
36. Saito T, Jones CC, Huang S, Czech MP, Pilch PF. The interaction of Akt with APPL1 is required for insulin-stimulated Glut4 translocation. J Biol Chem 282: 32280-32287, 2007.
37. Samuel VT, Petersen KF, Shulman GI. Lipid-induced insulin resistance: unravelling the mechanism. Lancet 375: 2267-2277, 2010.
38. Schmid PM, Resch M, Steege A, Fredersdorf-Hahn S, Stoelcker B, Birner C, Schach C, Buechler C, Riegger GA, Luchner A, Endemann DH. Globular and full-length adiponectin induce NO-dependent vasodilation in resistance arteries of Zucker lean but not Zucker diabetic fatty rats. Am J Hypertens 24: 270-277, 2011.
39. Son NH, Park TS, Yamashita H, Yokoyama M, Huggins LA, Okajima K, Homma S, Szabolcs MJ, Huang LS, Goldberg IJ. Cardiomyocyte expression of PPARgamma leads to cardiac dysfunction in mice. J Clin Invest 117: 2791-2801, 2007.
40. Summers SA. Ceramides in insulin resistance and lipotoxicity. Prog Lipid Res 45: 42-72, 2006.
41. Vu V, Liu Y, Sen S, Xu A, Sweeney G. Delivery of adiponectin gene to skeletal muscle using ultrasound targeted microbubbles improves insulin sensitivity and whole body glucose homeostasis. Am J Physiol Endocrinol Metab 304: E168-E175, 2013.
42. Wang Y, Cheng KK, Lam KS, Wu D, Huang Y, Vanhoutte PM, Sweeney G, Li Y, Xu A. APPL1 counteracts obesity-induced vascular insulin resistance and endothelial dysfunction by modulating the endothelial production of nitric oxide and endothelin-1 in mice. Diabetes 60: 3044-3054, 2011.
43. Wende AR, Abel ED. Lipotoxicity in the heart. Biochim Biophys Acta 1801: 311-319, 2010.
44. Wilson PW. Diabetes mellitus and coronary heart disease. Endocrinol Metab Clin North Am 30: 857-881, 2001.
45. Winzell MS, Ahren B. The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes. Diabetes 53, Suppl 3: S215-S219, 2004.
46. Wright JJ, Kim J, Buchanan J, Boudina S, Sena S, Bakirtzi K, Ilkun O, Theobald HA, Cooksey RC, Kandror KV, Abel ED. Mechanisms for increased myocardial fatty acid utilization following short-term high-fat feeding. Cardiovasc Res 82: 351-360, 2009.
47. Xin X, Zhou L, Reyes CM, Liu F, Dong LQ. APPL1 mediates adiponectin-stimulated p38 MAPK activation by scaffolding the TAK1-MKK3-p38 MAPK pathway. Am J Physiol Endocrinol Metab 300: E103-E110, 2011.
48. Yoo HH, Son J, Kim DH. Liquid chromatography-tandem mass spectrometric determination of ceramides and related lipid species in cellular extracts. J Chromatogr B Analyt Technol Biomed Life Sci 843: 327-333, 2006.
49. Young ME, McNulty P, Taegtmeyer H. Adaptation and maladaptation of the heart in diabetes: Part II: potential mechanisms. Circulation 105: 1861-1870, 2002.
50. Zhou L, Deepa SS, Etzler JC, Ryu J, Mao X, Fang Q, Liu DD, Torres JM, Jia W, Lechleiter JD, Liu F, Dong LQ. Adiponectin activates AMP-activated protein kinase in muscle cells via APPL1/LKB1-dependent and phospholipase C/Ca2/Ca2/calmodulin-dependent protein kinase kinase-dependent pathways. J Biol Chem 284: 22426-22435, 2009.
51. Zhou YT, Grayburn P, Karim A, Shimabukuro M, Higa M, Baetens D, Orci L, Unger RH. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci USA 97: 1784-1789, 2000.